Express News | Serina Therapeutics Q1 2024 R&D Expenses $1.1M Vs $400K Prior
Express News | Serina Therapeutics Inc: Substantial Doubt Regarding Ability of Company to Continue as a Going Concern
Express News | Serina Therapeutics-Believes Cash, Cash Equivalents on May 9 Not Sufficient to Satisfy Expected Operating, Other Funding Requirements for 12 Months
10-Q: Quarterly report
Earnings Flash (SER) SERINA THERAPEUTICS Reports Q1 Revenue $5,000
04:14 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (SER) SERINA THERAPEUTICS Reports Q1 Revenue $5,000
Express News | Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
Serina Therapeutics Files Registration Statement for Potential Offering of Common Stock, Warrants
Serina Therapeutics (SER) on Friday filed a registration statement for the potential offering of up to about 3 million common shares issuable upon warrant exercises, and up to about 1.5 million warran
Serina Therapeutics Files to Sell 1.5M Shares of Common Stock
Express News | Serina Therapeutics Appoints DR. Simba Gill as Executive Chairman
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersMSP Recovery (NASDAQ:LIFW) stock increased by 61.9% to $1.08 during Tuesday's pre-market session. The company's market cap stands at $15.9 million. Serina Therapeutics (AMEX:SER) stock moved up
Serina Therapeutics: Strategic Restructuring and Merger Success
News On AgeX Therapeutics Inc. (AGE) Now Under SER
News On AgeX Therapeutics Inc. (AGE) Now Under SER
Express News | Serina Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 61.6%
Serina Therapeutics Announces Completion of Merger With AgeX Therapeutics
Shares of Serina to commence trading on NYSE American under the ticker symbol "SER" on March 27, 2024Lead candidate SER-252, POZ-apomorphine preclinical studies anticipated to be completed in the fourth quarter of 2024;
AgeX Therapeutics GAAP EPS of -$13.73
AgeX Therapeutics Secures Funding, Details in SEC Report
AgeX Therapeutics Postpones Merger Completion With Serina
AgeX Therapeutics Expands Ties With JuvVentures Equity Deal
AgeX Therapeutics Secures $500K Convertible Note Deal
What's Going On With Penny Stock AgeX Therapeutics?
Serina Therapeutics Inc, a privately held, clinical-stage biotechnology company, entered into a License Agreement under which Pfizer Inc (NYSE:PFE) will license, on a non-exclusive basis, Serina's POZ
No Data